戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                         Data were available for 1 238 188 patients, covering 64 Natio
2                      Individual patient data were available for 10 553 patients.
3 air pollution exposure from previous studies were available for 10,000 children.
4 rticipated, complete, good-quality data sets were available for 100: 48 currently depressed older adu
5  strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%).
6                 Home-based vaccination cards were available for 1210 of 1934 children (63%) surveyed.
7 on on the apolipoprotein E (Apo-E) phenotype was available for 1259 men.
8                         Week 12 outcome data were available for 132 patients who initiated with mesal
9                         Primary outcome data were available for 134 (72%) patients at 12 months.
10                   Genital and anal specimens were available for 1348 MSW participants, and HPV genoty
11                      HbA1c data at follow-up were available for 146 people in the intervention group
12         Complete data on the primary outcome were available for 1497 infants (95.6%).
13                                  Data on BMI were available for 15 237 participants.
14                                    IQ scores were available for 150 patients (60 had received XRT, 90
15                         Primary outcome data was available for 152 control practices (dentists = 438)
16             Psychopathology and imaging data were available for 1538 youths.
17 at age of 8 years, and potential confounders were available for 1608 participants of the PIAMA birth
18 amples and biennial follow-up questionnaires were available for 164 BRCA1/2-mutation carriers with no
19                                         Data were available for 18 articles to be included in the met
20                  Gradable fundus photographs were available for 1809 participants who attended both b
21  randomized patients, baseline health status was available for 1833 individuals (950 TAVR, 883 SAVR)
22              Laboratory-confirmed HIV status was available for 19 330 respondents in Zambia and 18 00
23                            Day 35 MRD status was available for 191 patients.
24                        CYP2C19 genotype data was available for 2 423 patients and the final sample co
25 s enrolled, RT-PCR and serology test results were available for 2,023, including 1,087 children below
26                                         Data were available for 2,520 patients, and the most common c
27 2-72] years), complete 1-year follow-up data were available for 2164 (98.5%).
28                        After crossover, data were available for 22 itMSC patients.
29                                Complete data were available for 225 children; there were 87 cases of
30 lfur application and relevant covariate data were available for 237 and 205 children for whom we had
31                                 Outcome data were available for 248 plans (68% of plans operating pri
32                     Results: Sequencing data were available for 254 (56%) of the NeoALTTO participant
33                              Sequencing data were available for 254 (56%) of the NeoALTTO participant
34                              Urine specimens were available for 260 women with 85.4% from the America
35                            Neuroimaging data were available for 274 participants.
36 l risk factor measurements and location data were available for 28 887 (96%).
37                  The data of both US and CAP were available for 289 children.
38                                         Load was available for 290 of 291 cases with pneumococcal PCR
39                      In total, exposure data were available for 296 subjects, 188 of whom had complet
40 ilable for 3,637 (90%); hospital information was available for 3,531 (87%).
41  4,058 unique individual plans, network data were available for 3,637 (90%); hospital information was
42                                    Follow-up was available for 30 (75%) patients with crystalline LCP
43   Of the 503 study participants, MSI results were available for 303 patients (283 with microsatellite
44    As of Feb 28, 2015, follow-up information was available for 3083 patients for overall survival and
45 s; 17949 women [54.3%]), follow-up at 1 year was available for 31229 (94.5%).
46                                Complete data were available for 3152 participants (aged 15 years; 53%
47                           Clinical follow-up was available for 32 women; 5 died of cardiovascular com
48                  Complete (18)F-FDG PET data were available for 32 of 45 patients.
49                             Complete records were available for 323 women; 54 women met criteria for
50    Self-reported health and lifestyle habits were available for 34,202 participants in the Swedish Tw
51                       Results Biomarker data were available for 340 patients.
52                                    Full data were available for 3482 participants (48% men; mean age
53              Neurodevelopmental outcome data were available for 365 (81%) at a mean age of 23.6 month
54 outine growth data from birth to age 2 years were available for 3659 children between 1976 and 2012.
55 f corneal abnormalities, CH and CRF readings were available for 382 Indian persons.
56       High-confidence TOPKAT LOAEL estimates were available for 389 of 1026 hydraulic fracturing-rela
57 vived to 18- to 22-month follow-up, and data were available for 3892 of 4284 infants (90.8%).
58 -year data for this extended follow-up trial were available for 391 patients (78.2%) and information
59                                  RDT results were available for 40 of these surveys including 40 261
60                               Plasma samples were available for 40 patients after disease progression
61                 In the combined cohort, data were available for 40 patients at baseline and 38 patien
62                          Patient information was available for 41 of the isolates.
63                Five-year echocardiogram data were available for 424 patients after TAVR and 49 after
64                  Data on the primary outcome were available for 4274 of 4458 infants (96%) born at th
65                                Outcomes data were available for 435 of the 483 women (90.1%).
66                      Results Sufficient data were available for 4431 nodules (4315 benign nodules and
67                         Complete information was available for 456,711 (77.7%) of 587,710 women who h
68 91 patients (78.2%) and information on death was available for 459 patients (91.8%).
69 eceived eliglustat in the ENCORE trial; data are available for 46 patients who received eliglustat fo
70           Genome-wide association study data were available for 4609 individuals with ADHD, 9650 indi
71  of maternal concern about child weight.Data were available for 4689 mother-child dyads participating
72                                  Information was available for 47027 of 47124 births (99.8%) at surve
73 performance tests at the 4-y re-examinations were available for 480 men.
74 aging at baseline, longitudinal imaging data were available for 501 persons (mean age, 69.9 years; ag
75                         Primary outcome data were available for 525 (86%) participants.
76                Data to estimate NSP coverage were available for 57 countries, and for 60 countries to
77  Examination Survey (NHANES) III (1988-1992) were available for 6032 individuals aged 50 years old or
78     At long-term follow-up (results of which were available for 63% of the patients), the most common
79 ere eligible; however, AL data for both eyes were available for 64 patients at baseline and 69 patien
80 formation regarding post-Fontan intervention was available for 70%.
81                    Results from 2 IS samples were available for 719 children (79.4%).
82                                         Data were available for 75 countries, representing 2.106 bill
83                          The primary outcome was available for 7677 (96%) participants.
84 ort respiratory muscle strength measurements were available for 78 patients with ALS.
85 sts for Zika virus and brain imaging results were available for 79 (87%) cases; within these cases, t
86  functional magnetic resonance imaging scans were available for 82 subjects.
87                        Postintervention data were available for 8271 women and 5371 children younger
88 otid artery intima-media thickness (CCA-IMT) were available for 846 men.
89 6 months, data for the Oxford Shoulder Score were available for 90 patients assigned to decompression
90 ed case-control study, cognitive test scores were available for 924 male cases and 19,530 male contro
91                                Clinical data were available for 93 female %DHR(+) values were 46% (me
92                                          RSs were available for 979 patients.
93 2 children in the birth cohort, genetic data were available for 9912 adolescents.
94                                         Data were available for 992 (99.2%) trial participants (496 i
95 nd oral slope factors (OSFs) for cancer-that are available for a list of 1173 chemicals that the Unit
96 eous disease and specific therapies have not been available for a long time.
97 s freely available for academic research and is available for a fee for commercial use.
98 ultiple time points, and once a segmentation is available for a time sequence cells can be analyzed t
99                  Cord blood and age-14 serum were available for a subgroup (n = 40) and were also ana
100 ure has inherent complications and might not be available for all patients.
101  structured framework adapted from oncology) is available for all biomarkers, but their clinical vali
102                                 This package is available for all commonly used platforms.
103  The minfi package version 1.19.12 or higher is available for all platforms from the Bioconductor pro
104 ealth grants, and registered clinical trials were available for all academic cardiologists.
105  driver and selected nondriver myeloid genes were available for all patients.
106 ecause no pharmacokinetic data in recipients were available for all products.
107 ohort and, after quality control, 228 exomes were available for analyses.
108 ls in blood), only a limited number of cells are available for analysis.
109 ct that even if only one persistence diagram is available for analysis-the typical case for big data
110                    One induced sputum sample was available for analysis from 3772 (89.1%) of 4232 sus
111                   The remaining 384 patients were available for analysis (222 men [57.8%]; 162 women
112                 In group 1, 91 serum samples were available for analysis 1 month after booster immuni
113 pants (mean [SD] age, 31.3 [5.6] years), 166 were available for analysis at 24 months (retention, 80.
114            One hundred ninety-seven patients were available for analysis because 3 patients withdrew
115                       180-day follow-up data were available for analysis from 246 of 249 participants
116            Three hundred eighty-six patients were available for analysis in the intention-to-treat an
117                  Data from 27 patients (82%) were available for analysis in this study.
118  data from 597, 587, and 439 women or babies were available for analysis of obstetric, neonatal, and
119  both standard-dose and synthetic mammograms were available for analysis were retrospectively analyze
120 with Parkinson's disease from the PPMI study were available for analysis, and 317 patients with Parki
121 edish surgical departments, and 112 patients were available for analysis.
122 interquartile range (IQR), 28.0-42.0 years]) were available for analysis.
123 es in which data for fewer than ten children were available for analysis.
124  61 genomic data from Kilifi, eastern Kenya, were available for analysis.
125                 Reliable protocols have long been available for antibody staining of Drosophila whole
126 le for correlation analysis, and 12 patients were available for assessment of tumor overlap.
127 obank, in whom 77 of the 100 suggestive SNVs were available for association analysis with systolic BP
128  Several hydrolyzed cow's milk (CM) formulas are available for avoidance of allergic reactions in CM-
129  of now, no sensitive and inexpensive method is available for beta-A detection under physiological an
130      Proven and cost-effective interventions are available for both these common cancers, yet for so
131                  Although Gene Ontology (GO) is available for Caenorhabditis elegans, it does not inc
132                                  Few methods are available for calculating heritability for traits de
133 neuroendocrine tumors, and only limited data are available for cancer types with lower SSTR expressio
134 tional agreed standard outcomes (ICHOM) sets are available for cataract surgery (10 metrics) and macu
135 ual drug with pleiotropic beneficial effects is available for CF.
136  liver disease, and hepatitis C, but no data are available for CHB.
137 s, compositions, and constituent elements to be available for chemical and energy transformations thr
138                          PNIF normative data are available for children, adults and elderly subjects,
139 e is expected to be safe and immunogenic and is available for clinical development.
140  expected to be well tolerated in humans and is available for clinical evaluation.IMPORTANCE EBOV hem
141  repertoire of promising therapeutic options is available for clinical evaluation; however, the numbe
142                                      A model is available for comparing kinetic parameters and AC of
143 e that can be used even when few individuals are available for comparison or when genomes are sequenc
144 ries quiescent, stored in a latent form that is available for context-relevant activation.
145                           Seventeen patients were available for correlation analysis, and 12 patients
146 ls of the volumetric CT dose index (CTDIvol) are available for dedicated CT procedures on selected bo
147                             Easy-to-use APIs are available for developers to reuse and extend Web3DMo
148   Even though a variety of software packages is available for different aspects of the bioinformatics
149 E EBV causes human lymphomas, but few models are available for dissecting how EBV causes lymphomas in
150 each with distinct strengths and weaknesses, are available for distance-matrix based analysis of larg
151                    Many high-quality genomes are available for dixenous (two hosts) trypanosomatid sp
152 le HMMs, hit lists and other underlying data are available for download.
153 urce computational workflows and models will be available for download and application to local data.
154 code, implemented in C ++ on a linux system, is available for download at ftp://ftp.ncbi.nlm.nih.gov/
155                            Our code and data is available for download from github.com/medvedevgroup/
156 od has been implemented as an R package, and is available for download through Bitbucket.
157                                       ANARCI is available for download under GPLv3 license at opig.st
158   However, only a small number of CCS values are available for drugs, which limits the use of CCS as
159                         No licensed vaccines are available for either disease, but vaccines for both
160                 However, relatively few data are available for evaluation of zoonotic transmission.
161 elective synthesis of alpha-secondary amines are available (for example, from additions to protected/
162 e dough stage that insufficient thiol groups were available for forming dough layer interconnections
163       The package has a web-interface and it is available for free for academic use.
164                    The results of this study are available for further examination via NeuroVault.
165 entangled state with increased fidelity that is available for further use.
166                            Countless options are available for fusing magnetically active species wit
167 es developed by various computing techniques are available for gene prediction.
168 ning to physical linkage or genomic position are available for genetic markers, estimates of recombin
169  and controls, analyzable laboratory results were available for >/=96% of core specimens collected.
170                      Similar interpretations are available for H3N2, but right-censoring of titers ma
171 e acceptable, evidence based guidelines must be available for healthcare professionals and cleaning m
172          No once-daily single-tablet regimen is available for HIV-infected children under 12 years.
173                     The 10-year outcome data were available for ILA (n = 561) and mortality (n = 1,22
174                   High resolution structures are available for individual receptors dimers, but less
175          A specific therapeutic intervention is available for individuals testing positive for influe
176                       Many software packages are available for inferring local ancestry in admixed in
177 lts were imprecise and relatively few trials were available for interventions other than low-frequenc
178 porters, but limited structure-activity data are available for its analogs.
179  imaging (MRI), and computed tomography (CT) are available for its evaluation.
180 eceptors have been reported, no such ligands are available for KARs.
181 SNP)-SNP interactions, and no practical tool is available for large-scale investigations of the inter
182                                         GeNN is available for Linux, Mac OS X and Windows platforms.
183 dence regarding cardiovascular safety, which is available for lixisenatide, alogliptin, saxagliptin,
184 dity and mortality worldwide, but scant data are available for long-term outcomes in individuals outs
185                        Although limited data were available for low-income and middle-income countrie
186 disorders, to date, few effective treatments are available for lymphatic diseases.
187                 Although a plethora of tools are available for making pathogenicity predictions over
188                        Several interventions are available for management of obsessive-compulsive dis
189 -reported outcomes in clinical research, few are available for measuring upper limb function post-str
190                No completely accurate method is available for measuring CO in all patients.
191 h performance comparable to reference assays are available for molecular and serological diagnosis of
192 Phytomonas, but only fragmentary information is available for monoxenous (single-host) trypanosomatid
193 .2] years; 80.6% white), mortality follow-up was available for more than 98%.
194                                         Data were available for more than 550 000 individuals and 51
195         Since no actual physicochemical data is available for most derivatized compounds, the respons
196              Paired tumor and plasma samples were available for most patients (24 of 30).
197                  No algorithm or methodology is available for multi-factor analysis of differential c
198 nt intravenous iron formulations, which have been available for nearly a decade, seem to replenish ir
199 e high Fe/NOM ratio, sufficient or excess Fe was available for NOM removal, and coagulation proceeded
200 hs from cirrhosis in the West, but few tools are available for noninvasive diagnosis of alcoholic liv
201                           No definitive cure is available for OI and to develop novel drug therapies,
202 us recombination in embryonic stem cells and are available for only 25% of all mouse genes.
203 iversity, although comprehensive assessments are available for only 46% of species.
204 es and dynamics of polyubiquitin signals but are available for only five out of eight linkage types.
205           No data on large study populations are available for other phenols with possible endocrine-
206 sults Of patients, 82 were identified and 78 were available for outcome analysis; 32% received T-DM1
207 TB for a century, while drug treatments have been available for over 70 years; despite this, TB remai
208                     Methods to this end have been available for over a decade and, with a critical ma
209             Several therapeutic alternatives are available for palliative treatment.
210                        Few treatment options are available for patients with advanced and recurring e
211 ective first-line systemic treatment options are available for patients with advanced BRAF-mutated me
212           In addition, new treatment options are available for patients with advanced systemic mastoc
213      Purpose No effective salvage treatments are available for patients with advanced/recurrent thymo
214              Purpose Few therapeutic options are available for patients with Philadelphia chromosome-
215 eatments with a distinct mechanism of action are available for patients with platinum-refractory adva
216 ase, and we offer recommendations, when data are available, for patients with other clinical indicati
217  vertical clinical attachment level [CAL-V]) were available for patients at baseline and 12 months af
218 tense investigation, no interdictive therapy is available for PD.
219 iffusion from the gastric fluid, but no data are available for pepsin diffusion.
220                           Command line tools are available for performing integrated error correction
221     Unless more selective microglial markers are available for PET imaging, quantification of cytokin
222              Currently no licensed treatment is available for PIV infection.
223                            Whereas a vaccine is available for prevention of shingles, its efficacy de
224                     Prophylactic HPV vaccine is available for primary prevention.
225 patients received the intended treatment and were available for primary outcome measurement.
226 ingly, routine sequencing technologies-which are available for proteins and DNA and have revolutionis
227 ion regardless of how many sequence homologs are available for proteins in question.
228            As of August 2016, 238 cell lines are available for purchase.
229               Only a few existing techniques are available for quantification of structural changes a
230         Noncomparative and indirect evidence was available for questions about stopping versus contin
231  mPFC areas were registered to MNI space and are available for regional analysis of functional magnet
232                        Currently, two models are available for researchers to determine the oligomeri
233 Among enrolled patients whose medical charts were available for review post-discharge, 61 (27%) were
234                  Four large database studies were available for review, including 2 published after t
235 y (CT) and a CT angiography (CTA) at arrival were available for review.
236 lity in clinical studies, no equivalent tool is available for rodent animal samples.
237                   Comparable occupation data were available for Scotland in 1991, allowing assessment
238                            Although programs are available for sequence-based prediction of lipid acc
239        For remote programmatic access, API's are available for several programming languages.
240 ests that reduced amounts of CER3 transcript are available for siRNA synthesis, possibly because CER3
241                                   Activators are available for Sirt1 and exploit its unique N-terminu
242 t amounts of sequencing, more reads per site are available for SNP calling.
243 g pollution levels, very limited information is available for South Asia.
244                      The 5-year outcome data were available for spirometry (n = 697), cough (n = 722)
245 ure that appropriate amounts of each isoform are available for such disparate gene expression process
246                      However, scant guidance is available for surgeons seeking to develop peer-coachi
247 here time is a factor and only small volumes are available for testing.
248                                       Tissue was available for testing in 43 patients, and 32 (74%) h
249 ionization methods in mass spectrometry (MS) are available for the analysis of analytes with differen
250    Although several computational approaches are available for the annotation of spectra obtained fro
251 date no satisfactory technological solutions are available for the automated, miniaturized and integr
252                 No evidence-based guidelines are available for the definitive diagnosis or directed t
253 reds of genetically characterized cell lines are available for the discovery of genotype-specific can
254                                     Few data are available for the efficacy of "triple therapy" with
255                                 Limited data are available for the efficacy of triple therapy with tw
256                                 Limited data are available for the epidemiology and outcome of colore
257                          Although structures are available for the nucleocapsid protein in complex wi
258 , only inactivated influenza vaccines (IIVs) are available for the prevention of CIV in dogs.
259         A wide range of experimental systems are available for the study of spontaneous or environmen
260 of agents with distinct mechanisms of action are available for the treatment of patients with multipl
261               However, surprisingly, no data are available for the viscosity of supercooled water und
262 ecular structure of the detected compound to be available for the algorithm, the identification of no
263 ic traits, whole-genome marker profiles will be available for the entire set of breeding lines, enabl
264   No effective pharmacologic treatments have been available for the hyperphagia and obesity that char
265                                 Methods have been available for the last ten years to perform the inf
266              As yet, no open source software is available for the automatic gating of two channel ddP
267                    To date, no specific test is available for the diagnosis of the whole spectrum of
268                                      No tool is available for the early assessment of response to ant
269 arvation response (P0), very few information is available for the effect of excess phosphate Pi on pl
270                                 No treatment is available for the neurological manifestations of the
271  carbapenemases (KPC), no specific inhibitor is available for the phenotypic detection of OXA-48.
272 es but few are used to date, because no tool is available for the systematic evaluation of restrictio
273                        Level I evidence also was available for the role of macular grid laser photoco
274 5 receiving placebo) completed the study and were available for the primary analysis.
275      Data pertaining to 1,250,449 admissions were available for the study period.
276 s of the data in each report, and where data were available for the years before and after a ban, we
277                              Many strategies are available for their chemical macrocyclization, howev
278 elatively few commercially produced reagents are available for their study.
279 lishes limits to the microRNA machinery that is available for therapeutic siRNAs and suggests new par
280   Currently, no disease-modifying treatments are available for these disorders.
281 Unfortunately, little structural information is available for these complexes; indeed, for the highly
282 ificant loci, although no replication sample was available for these.
283 a caused by mutations in NOTCH3 No therapies are available for this condition.
284                 Online supplemental material is available for this article.
285  ISRCTN10888758 Online supplemental material is available for this article.
286  ISRCTN10888758 Online supplemental material is available for this article.
287                 Online supplemental material is available for this article.
288 (c)) RSNA, 2017 Online supplemental material is available for this article.
289 t glucose-responsive insulin-producing cells are available for transplantation.
290 ng domestic corneas in which fresher tissues were available for transplantation.
291    Several pharmacological treatment options are available for type 2 diabetes; however, many patient
292 eralized freeze-dried bone allografts (FDBA) are available for use in alveolar ridge preservation aft
293                                 The paradigm is available for use in 3-D and in 2-D (e.g., for the MR
294  and 58 samples from a total of 172 patients were available for validation of creatinine, TaC and CsA
295 tients with Parkinson's disease from LABS-PD were available for validation.
296 amine in wastewater, but limited information is available for viruses, especially ones of mammalian o
297 he intra-motif dependencies, but fewer tools are available for visualization.
298 n cross-platform C ++ and binary executables are available for Windows, macOS and Linux.
299 ugh preclinical and clinical trials and have been available - for years in some cases - before being
300 hough international reference materials have been available for years, the standardization of immunoa

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top